Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey

PU. Heuschmann, J. Kircher, T. Nowe, R. Dittrich, Z. Reiner, R. Cifkova, B. Malojcic, O. Mayer, J. Bruthans, D. Wloch-Kopec, C. Prugger, J. Heidrich, U. Keil,

. 2015 ; 22 (10) : 1354-1362. [pub] 20140819

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16021068

Grantová podpora
NT12102 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Previous cross-sectional surveys in different European countries within the EUROASPIRE programme demonstrated a high prevalence of modifiable risk factors, unhealthy lifestyles and inadequate drug treatment in coronary heart disease patients. Comparable data for ischaemic stroke patients is lacking. METHODS: A stroke-specific study module was added to the EUROASPIRE III core survey. This cross-sectional multicentre survey included consecutive patients with first-ever ischaemic stroke from four European countries. Data were obtained from medical records, patient interviews and patient examinations within 6-36 months after the stroke event. Control of modifiable risk factors after stroke was evaluated against contemporary European guidelines. RESULTS: A total of 881 patients was recruited. Median age was 66 years, 37.5% were female; average time from the stroke event to interview was 550 days. At the time of the interview, 17.6% of stroke patients smoked cigarettes, 35.5% had a body mass index ≥30 kg/m(2), 62.4% showed elevated blood pressure and 75.7% exhibited elevated LDL cholesterol levels. Antiplatelet drugs or oral anticoagulants were used by 87.2%, antihypertensive medication by 84.4% and statins by 56.8% of stroke patients. Among patients using antihypertensive drugs and lipid-lowering medication at the time of the interview, 34.3% and 34.4%, respectively, achieved target blood pressure and total cholesterol values according to current European guidelines. CONCLUSION: The EUROASPIRE III stroke-specific module shows that secondary prevention and risk factor control in patients after ischaemic stroke need to be improved in four European centres at the time of the study since about half of patients are not achieving risk factor targets defined in European guidelines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16021068
003      
CZ-PrNML
005      
20170425095311.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2047487314546825 $2 doi
024    7_
$a 10.1177/2047487314546825 $2 doi
035    __
$a (PubMed)25139770
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Heuschmann, Peter U $u Institute of Clinical Epidemiology and Biometry and Comprehensive Heart Failure Center, University of Würzburg, Germany Clinical Trial Center Würzburg, University Hospital Würzburg, Germany.
245    10
$a Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey / $c PU. Heuschmann, J. Kircher, T. Nowe, R. Dittrich, Z. Reiner, R. Cifkova, B. Malojcic, O. Mayer, J. Bruthans, D. Wloch-Kopec, C. Prugger, J. Heidrich, U. Keil,
520    9_
$a BACKGROUND: Previous cross-sectional surveys in different European countries within the EUROASPIRE programme demonstrated a high prevalence of modifiable risk factors, unhealthy lifestyles and inadequate drug treatment in coronary heart disease patients. Comparable data for ischaemic stroke patients is lacking. METHODS: A stroke-specific study module was added to the EUROASPIRE III core survey. This cross-sectional multicentre survey included consecutive patients with first-ever ischaemic stroke from four European countries. Data were obtained from medical records, patient interviews and patient examinations within 6-36 months after the stroke event. Control of modifiable risk factors after stroke was evaluated against contemporary European guidelines. RESULTS: A total of 881 patients was recruited. Median age was 66 years, 37.5% were female; average time from the stroke event to interview was 550 days. At the time of the interview, 17.6% of stroke patients smoked cigarettes, 35.5% had a body mass index ≥30 kg/m(2), 62.4% showed elevated blood pressure and 75.7% exhibited elevated LDL cholesterol levels. Antiplatelet drugs or oral anticoagulants were used by 87.2%, antihypertensive medication by 84.4% and statins by 56.8% of stroke patients. Among patients using antihypertensive drugs and lipid-lowering medication at the time of the interview, 34.3% and 34.4%, respectively, achieved target blood pressure and total cholesterol values according to current European guidelines. CONCLUSION: The EUROASPIRE III stroke-specific module shows that secondary prevention and risk factor control in patients after ischaemic stroke need to be improved in four European centres at the time of the study since about half of patients are not achieving risk factor targets defined in European guidelines.
650    _2
$a senioři $7 D000368
650    _2
$a ischemie mozku $x diagnóza $x epidemiologie $x terapie $7 D002545
650    _2
$a kardiovaskulární látky $x terapeutické užití $7 D002317
650    _2
$a komorbidita $7 D015897
650    _2
$a průřezové studie $7 D003430
650    _2
$a poskytování zdravotní péče $7 D003695
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dodržování směrnic $7 D019983
650    _2
$a průzkumy zdravotní péče $7 D019538
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a životní styl $7 D008019
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a prevalence $7 D015995
650    _2
$a recidiva $7 D012008
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a chování snižující riziko $7 D040242
650    _2
$a sekundární prevence $x metody $x normy $7 D055502
650    _2
$a kouření $x škodlivé účinky $7 D012907
650    _2
$a odvykání kouření $7 D016540
650    _2
$a cévní mozková příhoda $x diagnóza $x epidemiologie $x terapie $7 D020521
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a hmotnostní úbytek $7 D015431
650    _2
$a prevence kouření $7 D000074606
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kircher, Julia $u Institute of Clinical Epidemiology and Biometry and Comprehensive Heart Failure Center, University of Würzburg, Germany.
700    1_
$a Nowe, Tim $u Department of Neurology, Vivantes Klinikum Neukölln, Germany.
700    1_
$a Dittrich, Ralf $u Department of Neurology, University of Münster, Germany.
700    1_
$a Reiner, Zeljko $u Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia.
700    1_
$a Cífková, Renata, $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic Center for Cardiovascular Prevention, Charles University Medical School I and Thomayer Hospital, Prague, Czech Republic. $d 1955- $7 nlk20010094490
700    1_
$a Malojcic, Branko $u Department of Neurology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Croatia.
700    1_
$a Mayer, Otto, $u Department of Medicine II University Hospital Pilsen, Czech Republic. $d 1969- $7 xx0053346
700    1_
$a Bruthans, Jan, $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic Center for Cardiovascular Prevention, Charles University Medical School I and Thomayer Hospital, Prague, Czech Republic. $d 1948- $7 jn20000810219
700    1_
$a Wloch-Kopec, Dorota $u Department of Neurology, University of Krakow, Poland.
700    1_
$a Prugger, Christof $u INSERM U970, Paris Cardiovascular Research Centre, University Paris Descartes, Paris, France.
700    1_
$a Heidrich, Jan $u Epidemiological Cancer Registry North Rhine-Westphalia, Münster, Germany Institute of Epidemiology and Social Medicine, University of Münster, Germany.
700    1_
$a Keil, Ulrich $u Institute of Epidemiology and Social Medicine, University of Münster, Germany keilu@uni-muenster.de.
773    0_
$w MED00188754 $t European journal of preventive cardiology $x 2047-4881 $g Roč. 22, č. 10 (2015), s. 1354-1362
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25139770 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20170425095628 $b ABA008
999    __
$a ok $b bmc $g 1155738 $s 945596
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 22 $c 10 $d 1354-1362 $e 20140819 $i 2047-4881 $m European journal of preventive cardiology $n Eur J Prev Cardiol $x MED00188754
GRA    __
$a NT12102 $p MZ0
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace